PMID- 9329548
OWN - NLM
STAT- MEDLINE
DCOM- 19971029
LR  - 20041117
IS  - 0250-7005 (Print)
IS  - 0250-7005 (Linking)
VI  - 17
IP  - 4B
DP  - 1997 Jul-Aug
TI  - First clinical results with Enzymun-Test for free PSA.
PG  - 2861-4
AB  - BACKGROUND: Prostate Specific Antigen (PSA) is widely used for the detection and 
      monitoring of prostate cancer (CAP) but PSA is elevated in many patients with 
      benign prostatic hyperplasia (BPH). The measurement of free PSA may improve the 
      discrimination between CAP and BPH. MATERIAL AND METHODS: Free PSA (F-PSA) and 
      total PSA (T-PSA) were measured using kits based on the Enzymun-Test principle. 
      The patient population was composed of 38 untreated CAP patients, 76 BPH patients 
      and 29 prostatitis patients. RESULTS: At cut-off levels of 0.15 for the 
      F-PSA/T-PSA ratio and 10 ng/ml for T-PSA the specificity and sensitivity for 
      detecting CAP were respectively 87% and 84% for F-PSA/T-PSA ratio and 80% and 63% 
      for T-PSA. CONCLUSION: The F-PSA/T-PSA ratio is more powerful at discriminating 
      between CAP and BPH than T-PSA alone and may contribute to a reduction in 
      unnecessary invasive techniques.
FAU - Gilson, G
AU  - Gilson G
AD  - Laboratoire de Biochimie, Centre Hospitalier de Luxembourg, Luxembourg.
FAU - Lamy, S
AU  - Lamy S
FAU - Humbel, R L
AU  - Humbel RL
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - EC 3.4.21.77 (Prostate-Specific Antigen)
SB  - IM
MH  - Aged
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - Male
MH  - Middle Aged
MH  - Prostate-Specific Antigen/*blood
MH  - Prostatic Hyperplasia/blood
MH  - Prostatic Neoplasms/blood
MH  - Prostatitis/blood
MH  - Sensitivity and Specificity
EDAT- 1997/07/01 00:00
MHDA- 1997/11/05 00:01
CRDT- 1997/07/01 00:00
PHST- 1997/07/01 00:00 [pubmed]
PHST- 1997/11/05 00:01 [medline]
PHST- 1997/07/01 00:00 [entrez]
PST - ppublish
SO  - Anticancer Res. 1997 Jul-Aug;17(4B):2861-4.